Idenix Pharmaceuticals Interest Expense: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IDIX Interest Expense Rankings
| Overall | 99th percentile | 31 of 4677 |
| Sector | 98th percentile | 8 of 531 in Healthcare |
| Industry | 97th percentile | 4 of 165 in Biotechnology |
IDIX Interest Expense Range, Past 5 Years
| Minimum | 0.00 | Jun 2003 |
| Maximum | 0.00 | Jun 2003 |
| Average |
About Interest Expense
When companies borrow money to expand or maintain their business operations, they must pay interest on the money that they borrow. The interest expense is the annual accrued amount of interest that the company paid (or sometimes will have to pay) to its creditors.
YCharts includes both operating interest expense and non-operating interest expense in our numbers.
Learn More
You may also be interested in these IDIX related companies
IDIX News
@js_thorne $IDIX Alot going on behind the scenes so it CAN only be good going forward is my guess.
about a day ago by GArgondizza
about a day ago by GArgondizza
$IDIX big guys flushing stock and accumulating large positions?? That's my interperprtation of SEC filings
about 2 days ago by js_thorne
about 2 days ago by js_thorne
@StockRaker You were smart $IDIX. The table's been set on this one.
about 2 days ago by taketheplunge
about 2 days ago by taketheplunge
@GArgondizza @StockRaker you too my man, $idix im in it to win it just like i did with $inhx :)
about 2 days ago by BILLYTHE3RD
about 2 days ago by BILLYTHE3RD
@pjeffry000 @Eowen57 $idix Sorry about that volume, when i plugged in the stock i assumed the bid n ask and volume was all connected.
about 2 days ago by GArgondizza
about 2 days ago by GArgondizza
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm, 86k http://stks.co/2MAv
about 2 days ago by Eowen57
about 2 days ago by Eowen57
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm >> negative - seeing only 86K AH one of us is wrong
about 2 days ago by StockRaker
about 2 days ago by StockRaker
Barclays on U.S. Pharma: A New Era for Hep C Therapy - Starts Coverage on GILD & IDIX
Feb 10, 2:30PM Street Insider
Feb 10, 2:30PM Street Insider
Notable Analyst Rating Changes 02/10: (COP) (JDSU) (ATVI) Upgraded; (ORLY) (XCO) (AKS) Downgraded
Feb 10, 11:17AM Street Insider
Feb 10, 11:17AM Street Insider
A Forward Look, the Year Ahead - Featured Research on Inhibitex, Inc. and Idenix Pharmaceuticals, Inc.
Feb 07, 9:00AM Marketwire
Feb 07, 9:00AM Marketwire
Idenix (IDIX) announces removal of partial clinical hold on HCV nucleotide inhibitor, IDX184
Feb 03, 8:04AM Street Insider
Feb 03, 8:04AM Street Insider
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
Feb 03, 8:04AM Benzinga
Feb 03, 8:04AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDIX | 10.92 | -0.21 | -1.89% | 1.05B |
| PTEK | 0.62 | -0.01 | -0.90% | 4.30M |
| PNRA | 151.78 | 0.33 | 0.22% | 4.50B |
| PRGO | 93.31 | -0.74 | -0.79% | 8.70B |
| ABAX | 27.49 | -0.41 | -1.47% | 595.98M |
| ADVS | 27.23 | -0.44 | -1.59% | 1.38B |
| EBIX | 25.49 | -0.39 | -1.51% | 954.09M |
| NETC | 11.47 | -0.55 | -4.58% | 1.31B |
| CTCT | 30.63 | 0.22 | 0.72% | 910.94M |
| PETS | 12.08 | -0.04 | -0.33% | 245.71M |
